Inspire Medical Systems, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INSP research report →
Range $39 – $85
Price Chart
About the company
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U. S.
- CEO
- Timothy Herbert
- IPO
- 2018
- Employees
- 1,333
- HQ
- Golden Valley, MN, US
Get TickerSpark's AI analysis on INSP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.60B
- P/E
- 15.83
- Fwd P/E
- 42.34
- PEG
- 0.12
- P/S
- 1.81
- P/B
- 1.93
- EV/EBITDA
- 31.18
- Div Yield
- 0.00%
- Gross Margin
- 86.19%
- Op Margin
- 1.79%
- Net Margin
- 11.43%
- ROE
- 12.49%
- ROIC
- 1.84%
Latest fiscal year · YoY change
- Revenue
- $911.98M+13.6%
- Gross Profit
- $778.76M+14.6%
- Op Income
- $50.95M
- Net Income
- $145.42M+171.8%
- EPS
- $4.95+175.0%
- OCF Growth
- -10.2%
- FCF Growth
- -13.9%
- 52W High
- $147.03
- 52W Low
- $38.91
- 50D MA
- $68.41
- 200D MA
- $57.16
- Beta
- 0.65
- RSI (14)
- 28
- Avg Volume
- 763.41K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Inspire Medical delivered a softer third quarter but said coding clarity, Project Horizon investments, and a new Category I code position the company to return to growth in 2027.· November 2, 2026
- Q3 revenue was $206.7 million, down 7.9% year over year but up 3% sequentially; adjusted operating income was $1.9 million and adjusted diluted EPS was $0.14.
- Management said coding and reimbursement issues hurt Q3 by about $30 million and are expected to total about $120 million for the full year.
- Gross margin held at 86%, helped by a higher mix of Inspire V; operating cash flow was strong at $46.4 million in the quarter.
- Full-year 2026 revenue guidance was narrowed to $850 million-$860 million, with adjusted operating margin of 4.5%-5.5% and adjusted diluted EPS of $1.20-$1.40.
- Management guided to low single-digit year-over-year revenue growth in 2027, citing a more stable coding environment, Horizon-funded growth investments, and replacement revenue.
Third quarter revenue was $206.7 million, down 7.9% from a year ago and up 3% sequentially. Gross margin was 86%, up 20 basis points year over year. Operating loss was $28.7 million versus operating income of $9.6 million last year; adjusted operating income was $1.9 million versus $10.9 million last year. Diluted loss per share was $0.84, while adjusted diluted earnings per share was $0.14. Operating cash flow was $46.4 million, and cash and investments were $453.1 million with no debt. For 2026, management narrowed revenue guidance to $850 million-$860 million, expects adjusted operating margin of 4.5%-5.5%, diluted loss per share of $0.36-$0.10, and adjusted diluted EPS of $1.20-$1.40. The company said Q3 results were hit by coding and reimbursement challenges by about $30 million and now estimates the full-year impact at about $120 million. Management expects a significant sequential revenue increase in Q4, with international revenue roughly flat to Q4 last year, and said 2027 should return to low single-digit revenue growth.
Tim Herbert framed the quarter as a transition period, saying the company is moving through coding disruption toward a clearer reimbursement path. He emphasized that the stable temporary billing framework, the approved Category I CPT code for Inspire V effective January 1, 2028, and the RUC process all make him more confident in the company’s path forward. He also highlighted clinical evidence, the expansion into cardiology referral channels, and Horizon-funded investments in patient flow, education, and navigation as key strategic levers. His tone was noticeably more confident than last quarter, with repeated references to ‘turning the corner’ and being ‘in a much more favorable position’ on coding.
Matt Osberg said Q3 revenue was $206.7 million, down 7.9% year over year, with gross margin at 86% and adjusted operating expense of $176 million versus $181.8 million last year. He attributed the higher reported operating expenses to $24.1 million of restructuring charges tied to Project Horizon, $7 million of legal settlement expense, and higher legal fees, partly offset by lower marketing and stock-based compensation. He highlighted operating cash flow of $46.4 million in the quarter, year-to-date operating cash flow of $82.5 million, and a balance sheet with $453.1 million of cash and investments and no debt. On capital allocation, he pointed to free cash flow and Horizon as allowing continued investment in growth initiatives, while the full-year outlook was narrowed to $850 million-$860 million in revenue and adjusted operating margin of 4.5%-5.5%.
Analysts pressed management on whether the 2027 low-single-digit growth guide is conservative or if it leaves room for upside. Tim Herbert said the outlook already reflects market competition, some coding improvement, and a prudent view until final OPPS rules are published, while Matt Osberg said the company expects a large Q4 step-up and is focused on delivering it. Questions also focused on the $120 million reimbursement headwind, with management saying some patients are not lost permanently and that marketing and communication initiatives are designed to recapture utilization over time. On reimbursement and RUC, Herbert said the new Category I code should simplify the process in 2028, though reimbursement levels could still affect physician economics; he added that the company wants broad physician survey participation to support a fair valuation.
The call’s bull case is that the worst of the coding disruption may be behind the company, with management saying centers are becoming more comfortable with the temporary billing framework and that a new Category I code begins in 2028. Inspire V adoption is strong, gross margin remained high at 86%, and the company generated solid operating cash flow and maintained a strong balance sheet with no debt. Management also sees multiple growth supports for 2027, including Horizon-funded investments, higher ASC adoption, stronger patient flow, and eventual contribution from battery replacements.
The bear case is that 2026 is still being materially pressured by reimbursement and coding disruption, which management now estimates at about $120 million for the year. Q3 revenue was down 7.9% year over year, international revenue fell due to Germany destocking, and SG&A rose because of added marketing investment and restructuring charges. Analysts also raised concerns that 2027 growth may imply a slower underlying market rate than in prior years, and management acknowledged that reimbursement outcomes, RUC valuation, and physician economics still carry uncertainty.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.3%
- Shares Outstanding
- 28.97M
- Float Shares
- 27.31M
of shares held by institutions
285 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for INSP, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Apr 10, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.65M | ▼ 85.68K |
| Vanguard Group Inc | 2.95M | ▼ 46.92K |
| Wellington Management Group Llp | 2.38M | ▼ 153.29K |
| Soleus Capital Management, L.P. | 1.93M | ▲ 1.36M |
| Aqr Capital Management LLC | 1.86M | ▲ 1.55M |
| Ubs Group AG | 1.85M | ▲ 206.05K |
| Vanguard Portfolio Management LLC | 1.70M | ▼ 384.36K |
| D. E. Shaw & Co., Inc. | 1.47M | ▲ 281.93K |
| Nomura Holdings Inc | 1.37M | ▲ 1.37M |
| Deerfield Management Company, L.P. | 1.30M | ▼ 1.41M |
| Vanguard Capital Management LLC | 1.27M | ▲ 3.43K |
| State Street Corp | 1.25M | ▲ 43.77K |
Held by 367 ETFs
Biggest fund positions in INSP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 14, 26 | Ellis Gary Lee | other | 431 |
| Oct 14, 26 | Melenikiotou Georgia | other | 255 |
| Oct 14, 26 | CARREL MICHAEL H | other | 203 |
| Oct 14, 26 | Broader Shelley G | other | 284 |
| Aug 31, 26 | Kelly Jason P | other | 6,350 |
| Aug 7, 26 | Kelly Jason P | sell | 963 |
| Jul 31, 25 | Mann Melissa | other | 326 |
| Jul 31, 26 | Mann Melissa | other | 326 |
| Jul 20, 26 | CARREL MICHAEL H | other | 5,631 |
| Jul 20, 26 | CARREL MICHAEL H | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INSP coverage
Recent articles, reports, and earnings notes.
Want a deeper read on INSP?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Inspire Medical Systems, Inc. to Present at the Piper Sandler 38th Annual Healthcare Conference
globenewswire.com · Nov 17
Inspire Medical Systems, Inc. $INSP Position Trimmed by Alberta Investment Management Corp
defenseworld.net · Nov 17
Here's Why You Should Retain INSP Stock in Your Portfolio for Now
zacks.com · Nov 11
INSP Is Up 12.1% in Three Months: Can Its Rally Continue From Here?
zacks.com · Nov 10
Inspire Medical Systems: The Moat Just Passed Its Worst-Case Stress Test
seekingalpha.com · Nov 4
Inspire Medical Systems, Inc. to Present at the Stifel 2026 Healthcare Conference
globenewswire.com · Nov 3
These Analysts Increase Their Forecasts On Inspire Medical After Strong Q3 Results
benzinga.com · Nov 3
Inspire Medical Systems, Inc. (INSP) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
